CataX AI Completes RMB 40 Million Seed Round, Using Agents to Accelerate Clinical Development of New Drugs
CataX AI has completed a RMB 40 million seed round, incubated and exclusively invested in by Qiming Venture Partners. This Agent-native innovative drug R&D company focuses on the clinical development side, building a "Clinical-of-One" full-stack clinical organization paradigm, and plans to advance preclinical and early-clinical-stage assets through licensing-in or co-development to complete clinical proof of concept (PoC).
Topics
Body · AI translation
Related topics top start Related topics top end Futures promotion begin Futures promotion end Miaopai begin Miaopai end Video player start Video player end Market chart begin Market chart end
Sina Tech News, November 16 afternoon: Recently, Shanghai CataX AI Biotechnology Co., Ltd. (hereinafter referred to as CataX AI) announced the completion of a 40 million RMB seed round of financing, incubated and exclusively invested by Qiming Venture Partners.
According to the introduction, CataX AI was founded in Shanghai and is an innovative drug R&D company native to agents (Agent). CataX AI focuses on the clinical development side, uses agents as its technical foundation, and thereby builds the new organizational paradigm of "Clinical-of-One" (full-stack clinical), planning to advance preclinical and early clinical-stage assets to complete clinical proof of concept (PoC) through licensing-in or co-development.
Wang Zilong, founder and CEO of CataX AI, said: "Thank you to Qiming Venture Partners for its support and trust in the team. Medicine determines why we set out; AI determines how we do it. At CataX AI, Agent is the organization's infrastructure, not an add-on tool. With the full support of technology and the expert team, one clinical lead can coordinate the entire project: data research, document drafting, and data processing are handed over to specialized agents, while key decisions are checked by humans; the experience of each project is accumulated and continuously reused, driving the organization to keep iterating. This is Clinical-of-One. We hope to give time back to science and enable promising drugs to obtain clinical validation earlier."
Chen Kan, partner at Qiming Venture Partners and co-head of the healthcare innovation sector, said: "The application of AI in the drug discovery stage has become increasingly mature, and clinical development is becoming a link with greater value and greater need for reconstruction. Since its first day of founding, CataX AI has built its organization in an Agent-native way, and Clinical-of-One represents one possibility for the next generation of clinical R&D organizations. Dr. Wang Zilong has both systematic clinical medicine training and frontier AI research experience at Microsoft Research Asia, and co-founder Jiang Zhemin has more than 15 years of clinical development experience. Such a combination is very rare. We look forward to working hand in hand with the team to create more possibilities for the clinical development and global cooperation of innovative drugs." news_keyword_pub,stock, iframe below the main text iframe below the main text General statement General statement QR code at the end start QR code at the end start
QR code at the end start QR code at the end start Editor name and work code
Editor name and work code